Merck & Co. shares advanced in the extended session Tuesday after the drug maker said the Food and Drug Administration will grant a priority review for one of its lung cancer treatments. Merck shares rose 2.2% to $61.25 after hours, following a 1.9% decline in the regular session. Merck said the FDA accepted its marketing application for Keytruda as a first-line treatment lung cancer along with chemotherapy, with an expected decision date on the application by May 10.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News